Burning Rock Biotech
BNR
50 hedge funds and large institutions have $67.1M invested in Burning Rock Biotech in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 13 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
9% more funds holding
Funds holding: 46 → 50 (+4)
0.56% less ownership
Funds ownership: 3.38% → 2.82% (-0.56%)
76% less capital invested
Capital invested by funds: $274M → $67.1M (-$207M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$15.7M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$8.55M |
| 3 |
Renaissance Technologies
New York
|
+$4.4M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.72M |
| 5 |
Barclays
London,
United Kingdom
|
+$3.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$38.3M |
| 2 |
MICM
Matthews International Capital Management
San Francisco,
California
|
-$14.1M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$7.79M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$6.13M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$6.13M |
BNR Hedge Fund Activity: Q2 2022 in Review
50 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q2 2022, worth a combined $67.1M — down 76% from $274M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BNR positions and 13 closed out — a net gain of 5 holders — while 13 added to existing stakes and 10 trimmed.
The largest buyer was Kynam Capital Management, adding an estimated $15.7M. The largest seller was Baillie Gifford & Co, cutting an estimated $38.3M.
- 50 institutional investors held Burning Rock Biotech (BNR) as of Q2 2022, up from 46 in Q1 2022.
- Funds reported $67.1M of Burning Rock Biotech stock for Q2 2022, down 76% quarter-over-quarter.
- 18 funds opened new Burning Rock Biotech positions in Q2 2022 and 13 closed out, a net change of +5 holders.
- The largest Burning Rock Biotech buyer in Q2 2022 was Kynam Capital Management, an estimated $15.7M added.
- The largest Burning Rock Biotech seller in Q2 2022 was Baillie Gifford & Co, an estimated $38.3M sold.
Based on aggregated 13F filings for Q2 2022.